Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

Published:2019-12-20 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Deak Dalma,Pop Cristina,Zimta Alina-Andreea,Jurj Ancuta,Ghiaur Alexandra,Pasca Sergiu,Teodorescu Patric,Dascalescu Angela,Antohe Ion,Ionescu Bogdan,Constantinescu Catalin,Onaciu Anca,Munteanu Raluca,Berindan-Neagoe Ioana,Petrushev Bobe,Turcas Cristina,Iluta Sabina,Selicean Cristina,Zdrenghea Mihnea,Tanase Alina,Danaila Catalin,Colita Anca,Colita Andrei,Dima Delia,Coriu Daniel,Einsele Hermann,Tomuleasa Ciprian

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference169 articles.

1. Childhood acute lymphoblastic leukemia: progress through collaboration;Pui;JCO,2015

2. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993;Rowe;Blood,2005

3. Outcome of 609 adults after relapse of acute lymphoblastic leukemia. (ALL); an MRC UKALL12/ECOG 2993 study;Fielding;Blood,2007

4. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia;Kantarjian;N Engl J Med,2017

5. New standard for relapsed ALL;Hutchinson;Nat Rev Clin Oncol,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription;Cell Death & Disease;2024-08-26

2. Unravelling CD24‐Siglec‐10 pathway: Cancer immunotherapy from basic science to clinical studies;Immunology;2024-08-11

3. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions;Cancer Immunology, Immunotherapy;2024-01-27

4. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease;British Journal of Haematology;2023-05-08

5. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?;Cancers;2022-12-07